10x Genomics Inc
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
TXG$62.90-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands)
| December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net loss | $(255,099) | $(166,000) | $(58,223) |
| Other comprehensive income (loss), net of tax: | |||
| Unrealized gains (losses) on available-for-sale marketable securities | 2,210 | (4,116) | — |
| Realized loss on available-for-sale marketable securities reclassified into net loss | 1,718 | — | — |
| Foreign currency translation adjustment | (22) | (241) | 72 |
| Other comprehensive income (loss), net of tax | 3,906 | (4,357) | 72 |
| Comprehensive loss | $(251,193) | $(170,357) | $(58,151) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.